Can-Fite BioPharma
  • ABOUT
    • Overview
    • Management
    • Drug Development Team
    • Board of Directors
    • Corporate Partnerships
  • SCIENCE
    • Technology Platform
    • Scientific Publications
  • PIPELINE
    • Overview
    • Piclidenoson (CF101)
    • Namodenoson (CF102)
    • CF602
    • Cannabinoids
  • INVESTORS
    • Overview
    • News & Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Fillings
    • Corporate Governance
    • Shareholders Meetings
  • CONTACT

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In The News
    • Research
    • Events Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Video
    • Management
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Governance Documents
  • Shareholders Meetings
  • News & Events

  • Overview
  • Press Releases
  • In The News
  • Research
  • Events Calendar
  • Presentations
  • Email Alerts
Jul 08, 2021 7:00am EDT

Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study

Jun 28, 2021 7:00am EDT

Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets

Jun 16, 2021 7:45am EDT

Can-Fite Receives Notice of Patent Allowance in China for NASH Treatment

Jun 02, 2021 7:35am EDT

Can-Fite To Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson

Jun 02, 2021 7:00am EDT

Can-Fite to Present at BIO Digital International Convention & Conduct One-on-One Meetings with Potential Partners on June 10-18, 2021

May 27, 2021 7:00am EDT

Can-Fite Reports First Quarter 2021 Financial Results & Provides Clinical Update

May 27, 2021 6:00am EDT

Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

May 06, 2021 7:00am EDT

Can-Fite to Present at Benzinga’s Global Small Cap Conference on May 13, 2021

Apr 29, 2021 7:00am EDT

Can-Fite’s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021

Apr 22, 2021 7:20am EDT

Can-Fite Expands its Phase II COVID-19 Study to Europe

  • arrow_back
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 45
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • HOME
  • CONTACT

© 2025 Can-Fite All Rights Reserved

BrandWiz - Branding